Acculis' new device for destroying unwanted tissues receives European CE Mark clearance

Acculis Limited today announced the regulatory clearance of its revolutionary new device for destroying unwanted tissues, such as liver tumours. The clearance under the European CE Mark system allows the company to begin deliveries for treating patients throughout Europe and elsewhere where the CE Mark system is recognised. The device is a single high power high frequency 2.45GHz microwave needle that burns a 5cm sphere of tissue in just 5 minutes which is between 3 to 10 times faster than old school radiofrequency based systems or lower frequency 915MHz microwave systems. "This system gives surgeons and interventionalists the ability to treat previously inoperable patients and early data suggests significantly improved clinical outcomes for tumour control." said Mr David Lloyd who fathered the system along with Professor Nigel Cronin and his microwave science team from the University of Bath, England.

“This system gives surgeons and interventionalists the ability to treat previously inoperable patients and early data suggests significantly improved clinical outcomes for tumour control.”

This new device is the latest in a series of product innovations from specialist microwave technology company Acculis based in Hampshire, England. "Our Acculis MTA system revolutionises ablative therapy. Its sheer speed and power allows decisive new therapy for patients for whom there was previously little hope. We have been delighted with the results of our first devices launched in 2008 and 2009 to the liver surgery community and this new device makes the technology available to the whole interventional radiology community. We expect first deliveries in the UK and Europe over the coming weeks." Said Acculis CEO Stuart McIntyre. Data to be presented at the forthcoming international liver surgeons’ convention IHPBA in Buenos Aires shows promising outcomes when compared to current ablative therapies such as radiofrequency ablation and cryotherapy, the company stated.